MicroRNA-490-3p inhibits migration and chemoresistance of colorectal cancer cells via targeting TNKS2

Li, Jing; Mo, Rubing; Zheng, Lei

doi:10.1186/s12957-021-02226-1

Cited by 7 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, miR-490-3p directly controlled RAB14 in CRC cells [48]. Expression of miR-490-3p affected cell viability and resistance to chemotherapy in CRC cells through regulating TNKS2 [35]. Our data also showed that ectopic expression of miR-490-3p significantly blocked malignant phenotypes of CRC cells, which is completely consistent with previous reports.…”

Section: Discussionsupporting

confidence: 92%

“…Previous studies showed that tumor-suppressive function of miR-490-3p in CRC cells through targeting several oncogenic genes [35,36,47,48]. For example, ectopic expression of miR-490-3p blocked migration and invasion abilities in CRC cells [47].…”

Section: Discussionmentioning

confidence: 99%

“…To date, high-throughput technologies (e.g., oligo-microarrays, PCR-based arrays, and RNA sequences) have enabled the construction of CRC miRNA expression signatures, revealing aberrant expression of many miRNAs [24,[28][29][30][31][32][33][34]. Previous studies have shown that miR-490-3p, miR-195-5p, and miR-30a-5p, which are frequently downregulated in CRC, function as tumor-suppressive miRNA in CRC cells [25,[35][36][37][38][39]. These miRNAs were included in the signature we created in this study.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

RNA-Sequencing Based microRNA Expression Signature of Colorectal Cancer: The Impact of Oncogenic Targets Regulated by miR-490-3p

Hozaka

Kita

Yasudome

et al. 2021

IJMS

View full text Add to dashboard Cite

To elucidate novel aspects of the molecular pathogenesis of colorectal cancer (CRC), we have created a new microRNA (miRNA) expression signature based on RNA-sequencing. Analysis of the signature showed that 84 miRNAs were upregulated, and 70 were downregulated in CRC tissues. Interestingly, our signature indicated that both guide and passenger strands of some miRNAs were significantly dysregulated in CRC tissues. These findings support our earlier data demonstrating the involvement of miRNA passenger strands in cancer pathogenesis. Our study focused on downregulated miR-490-3p and investigated its tumor-suppressive function in CRC cells. We successfully identified a total of 38 putative oncogenic targets regulated by miR-490-3p in CRC cells. Among these targets, the expression of three genes (IRAK1: p = 0.0427, FUT1: p = 0.0468, and GPRIN2: p = 0.0080) significantly predicted 5-year overall survival of CRC patients. Moreover, we analyzed the direct regulation of IRAK1 by miR-490-3p, and its resultant oncogenic function in CRC cells. Thus, we have clarified a part of the molecular pathway of CRC based on the action of tumor-suppressive miR-490-3p. This new miRNA expression signature of CRC will be a useful tool for elucidating new molecular pathogenesis in this disease.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

RNA-Sequencing Based microRNA Expression Signature of Colorectal Cancer: The Impact of Oncogenic Targets Regulated by miR-490-3p

Hozaka

Kita

Yasudome

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…In the same way, tankyrase 1 and 2 (TNKS1/2) are regulators of Wnt signaling by controlling the activity of the β-catenin destruction complex by reducing G1 cell cycle arrest and senescence ( Foronda et al, 2019 ). Mechanistically, TNKS2 is targeted by miR-490-3p, and its increased expression promoted the chemoresistance of colorectal cancer cells ( Li J. et al, 2021 ).…”

Section: Micrornas Involved In Ddp-chemoresistancementioning

confidence: 99%

Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review

Loren

Saavedra

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cisplatin (DDP) is a well-known anticancer drug used for the treatment of numerous human cancers in solid organs, including bladder, breast, cervical, head and neck squamous cell, ovarian, among others. Its most important mode of action is the DNA-platinum adducts formation, inducing DNA damage response, silencing or activating several genes to induce apoptosis; these mechanisms result in genetics and epigenetics modifications. The ability of DDP to induce tumor cell death is often challenged by the presence of anti-apoptotic regulators, leading to chemoresistance, wherein many patients who have or will develop DDP-resistance. Cancer cells resist the apoptotic effect of chemotherapy, being a problem that severely restricts the successful results of treatment for many human cancers. In the last 30 years, researchers have discovered there are several types of RNAs, and among the most important are non-coding RNAs (ncRNAs), a class of RNAs that are not involved in protein production, but they are implicated in gene expression regulation, and representing the 98% of the human genome non-translated. Some ncRNAs of great interest are long ncRNAs, circular RNAs, and microRNAs (miRs). Accumulating studies reveal that aberrant miRs expression can affect the development of chemotherapy drug resistance, by modulating the expression of relevant target proteins. Thus, identifying molecular mechanisms underlying chemoresistance development is fundamental for setting strategies to improve the prognosis of patients with different types of cancer. Therefore, this review aimed to identify and summarize miRs that modulate chemoresistance in DDP-resistant in the top five deadliest cancer, both in vitro and in vivo human models.

show abstract

“…The study conducted by Sasaki et al [106] just recently highlighted the importance of plasma miR-33a-5p to act as an effective biomarker for foresight on metastatic CRC chemotherapeutic success, focusing specifically on the typical first-line treatment combination of chemotherapeutic drugs, namely fluoropyrimidine + oxaliplatin + bevacizumab. The results of this study reveal that non-responders to CRC chemotherapeutic cycles had upregulated miR-33a-5p, indicating that patients with downregulated plasma levels for this miRNA would be more likely to respond to CRC chemotherapy [106] .…”

Section: Mirna Biomarkers For Crc Chemoresistancementioning

confidence: 99%

Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance

Buhagiar¹,

Seria²,

Borg³

et al. 2021

CDR

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer worldwide. It has also been demonstrated that over the last ten years the incidence of CRC among younger people below the age of 50 is also increasing. Screening for colorectal cancer is of utmost importance; the rationale behind screening is to target the malignancy and reduce the incidence and mortality of the disease. Diagnostic methods to screen for incidence or relapse are therefore a requisite to detect cancer as early as possible. Scientific findings demonstrate that many deaths are due to lack of screening and therefore early identification will lead to greater survivability. In colorectal cancer, diagnostic tests include liquid biopsy biomarkers. Since the discovery of microRNAs (miRNAs), many studies have demonstrated the relationship between miRNAs and the various sub-types of CRC. Several miRNAs have been identified after analysing serum or plasma samples in patients, and such miRNAs were found to be significantly dysregulated. Such findings place the possibility of miRNAs to be at the epicentre of novel diagnostic techniques for CRC identification and sub-type stratification, including other characteristics associated with CRC development such as patient prognosis. The following review serves to underline the latest findings for miRNAs with such potential for routine diagnostic employment in CRC diagnostics and treatments.

show abstract

MicroRNA-490-3p inhibits migration and chemoresistance of colorectal cancer cells via targeting TNKS2

Cited by 7 publications

References 30 publications

RNA-Sequencing Based microRNA Expression Signature of Colorectal Cancer: The Impact of Oncogenic Targets Regulated by miR-490-3p

RNA-Sequencing Based microRNA Expression Signature of Colorectal Cancer: The Impact of Oncogenic Targets Regulated by miR-490-3p

Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review

Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance

Contact Info

Product

Resources

About